Disease relapse is the commonest cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplasia yet treatment options for such patients remain extremely limited. Azacitidine is an important new therapy in high risk myelodysplasia and acute myeloid leukaemia but its role in patients who relapse post allograft has not been defined.
Abstract:
Disease relapse is the commonest cause of treatment failure after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplasia yet treatment options for such patients remain extremely limited. Azacitidine is an important new therapy in high risk myelodysplasia and acute myeloid leukaemia but its role in patients who relapse post allograft has not been defined.
We studied the tolerability and activity of Azacitidine in 181 patients who relapsed after an allograft for acute myeloid leukaemia (n=116) or myelodysplasia (n=65). 69 patients received additional donor lymphocyte infusions.
46 of 157 (25%) assessable patients responded to Azacitidine therapy: 24 (15%) achieving a complete remission and 22 a partial remission. Response rates were higher in patients transplanted in complete remission (p= 0.04) and those transplanted for myelodysplasia (p= 0.023). In patients who achieved a complete remission the 2 year overall survival was 48% versus 12% for the whole population.
Overall survival was determined by time to relapse post-transplant > 6 months (p= 0.001) and percentage of blasts in the bone marrow at time of relapse (p= 0.01). The concurrent administration of donor lymphocyte infusion did not improve either response rates or overall survival in Azacitidine treated patients. An Azacitidine relapse prognostic score was developed which predicted 2 year overall survival ranging from 3-37% (p=0.00001).
We conclude Azacitidine represents an important new therapy in selected patients with acute myeloid leukaemia/myelodysplasia who relapse after allogeneic stem cell transplantation. Prospective studies to confirm optimal treatment options in this challenging patient population are required.
Introduction:
Allogeneic stem cell transplantation (SCT) is an important curative option in patients with high-risk acute myeloid leukemia (AML) and myelodysplasia (MDS). The major cause of treatment failure remains disease relapse, which occurs in 40-70% of patients 1 , 2 . Little progress has been made to date in developing effective treatment options for patients with recurrent disease after allogeneic SCT and the great majority remain destined to die of resistant disease 3 . Although a small number of patients with disease recurrence can survive long term after a second transplant or donor lymphocyte infusion (DLI) the success of both these treatment modalities is contingent on the prior acquisition of morphological remission with salvage therapy 4 , 5 . At present the only established salvage option for patients who relapse post allograft is intensive chemotherapy which is variably effective, with reported CR rates of 15-30% and is often poorly tolerated in this heavily pre-treated population patients [3] [4] [5] . The low rates of response to myelosuppressive chemotherapy, coupled with its substantial toxicity and requirement for lengthy hospitalization, makes the identification of more effective and better tolerated re-induction therapies for patients relapsing after allogeneic SCT a significant unmet clinical need.
Azacitidine (AZA) is a DNA methyltransferase inhibitor (DNMTI) which demonstrates significant clinical activity in patients with AML and high risk MDS 6, 7 . The mechanism of the anti-tumor activity of AZA has not been determined but may be consequent upon its ability to reverse epigenetically silenced pro-apoptotic pathways. AZA also has the capacity to up-regulate the expression of epigenetically silenced tumor antigens and can induce a CD8+ T cell response to tumor antigens post-transplant raising the possibility that it may have the potential to augment a graft-versusleukemia (GVL) response 8, 9 . A number of small series have reported that AZA can induce remissions in patients who relapse after an allogeneic transplant raising the possibility that this agent represents a potentially new treatment strategy in this challenging patient population [10] [11] [12] . Furthermore, it has been suggested in single arm studies that AZA may augment the anti-tumor activity of DLI in patients who relapse after an allograft 13 . However, importantly, to date there has been no systematic analysis of the clinical activity of AZA in patients who have relapsed after an allograft for AML or MDS or whether its activity is increased by the concurrent administration of DLI.
Methods:
Patients: regimen according to EBMT criteria 16 .
Azacitidine therapy:
AZA was administered at a dose of 75 mg/m 2 for 5-7 consecutive days every month.
The median time from relapse to commencement of AZA was 11 days (range 1-30 days). The median duration of AZA treatment was 53 days (2-1196) and the median total AZA dose delivered to the study population was 1050 mg/m 2 (75-10500). 69 patients received DLI in addition to AZA treatment, 39 of whom received DLI within two months of commencing AZA salvage and in the absence of a clinical response.
35 patients proceeded to a second allogeneic transplant after AZA salvage therapy at a median of 119 days (range 12-1183 days) after the commencement of salvage AZA. 24 patients were allografted before an assessment of response to AZA salvage was made (median 82 days), 6 of whom were transplanted after acquisition of a major response (CR/PR) following AZA therapy and 5 after loss of a major response to AZA. Non-hematological toxicities were graded using the National Cancer
Institute's Common Terminology Criteria for Adverse Events (http://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm).
Hematological toxicity was not assessable in the presence of active leukemia.
Response criteria
Response to AZA was assessed by conventional morphological criteria and evaluated in patients who had received AZA alone or AZA in combination with DLI.
Complete response (CR) was defined as acquisition of <5% blasts on bone marrow assessment. Partial response (PR) was defined using the criteria defined by Cheson et al 17 .
Statistical analysis
The primary endpoint of the study was OS. Secondary endpoints were response rate (CR or PR). Outcome parameters were measured from the date of commencement of AZA. Cumulative incidence curves were used to estimate CR and response rate, as death was a competing event 18 . The probability of OS was calculated using the Kaplan-Meier estimate. Two Cox proportional hazards models were developed, including or not DLI within two months as a time dependent variable. Overall survival after AZA salvage therapy:
The median follow up after commencement of AZA therapy was 24 months (2-72). In a time dependent multivariable analysis ( Table 4) 
The Development of the AZA Relapse Prognostic Score (ARPS):
Using factors previously identified to determine survival after AZA therapy it was possible to create a scoring system based on interval from transplant to relapse and blast percentage in the bone marrow at the time of relapse. In the ARPS scoring system the interval from transplant to relapse was assigned 2 points if less than 6 months, 1 if 6-12 months and 0 if greater than 12 months. A blast percentage greater than the median (20%) at relapse was assigned 1 point. Utilizing the ARPS predicted the likelihood of achieving both a CR and major response as well as 2 year OS after AZA salvage therapy (Table 5 and Figure 1 ).
Discussion:
The ability of AZA to produce major clinical responses in a proportion of patients who relapse after an allograft for AML or MDS conclusively identifies this agent as a new treatment option in this challenging clinical setting. Furthermore, our study, which represents the first systematic analysis of activity of AZA in patients relapsing posttransplant, defines factors predicting the likelihood of response, which will assist its logical deployment. A second transplant or administration of DLI represent the only treatment modalities with the capacity to deliver long term survival in patients with recurrent disease after an allogeneic transplant but their utility is almost entirely dependent on the prior acquisition of a morphological remission 3 . Currently the only established therapy in this patient population is intensive chemotherapy which has been reported to result in 2 nd CR rates in the region of 15-30% but is associated with significant toxicity and prolonged in-patient stays [3] [4] [5] . Our data permits, for the first time, the identification of patients with a significant chance of responding to AZA in whom DLI or a second transplant can be delivered with potential curative effect. The retrospective nature of these data, in common with previous reports of outcome after intensive chemotherapy, introduce significant potential selection bias. We have deliberately only studied patients who received AZA within a month of relapse in order to mimimize this bias. It will be important, however, for future studies addressing this important clinical challenge to be performed prospectively, either in a registration study or as a randomized comparison of AZA and intensive chemotherapy.
For patients who have experienced the rigors of a previous allograft, considerations of both treatment toxicity and patient disposition are important. In general AZA reinduction was well tolerated. Although approximately 30% of patients experienced Grade 3-4 non-hematological toxicities these were principally infectious and likely to be consequent upon the cytopenias associated with disease relapse rather than being directly attributable to AZA. There was a notably low incidence of GVHD observed in this study, which is surprising given the likelihood that many patients had undergone a rapid taper immunosuppression taper. Although this observation requires prospective validation it is consistent with the demonstration that AZA has the capacity to expand regulatory T cells post-transplant, which may result in a reduced risk of GVHD 19, 20 . An additional, potentially valuable benefit of the use of AZA compared with intensive chemotherapy in this patient population is the opportunity to deliver salvage therapy as an out-patient. The other pressing therapeutic challenge in the management of patients with relapsed disease is to maximize the curative potential of a second transplant in patients who have responded to salvage therapy. Transplant toxicity remains substantial in this setting and it is possible that AZA results in less organ toxicity than conventional chemotherapy.
In light of the significant number of patients who do not respond to AZA therapy an important question raised by our data is whether it is possible to increase the response rate to AZA in this patient population. One proposed approach has been to combine AZA with DLI
21
. This is the first study to study the impact of concurrent DLI on AZA response and we failed to demonstrate any benefit associated with the coadministration of DLI. Co-administration of a histone deacetylase inhibitor, such as sodium valproate or vorinostat, may increase both the overall response rate and its speed in patients with AML and MDS 22, 23, 24 and it would be interesting to study such an approach in patients who relapse after an allograft. AZA has previously been shown to up-regulate the expression of epigenetically silenced tumor antigens, and one of its mechanisms of action in patients who have relapsed after an allogeneic transplant is the augmentation of a GVL effect. Consequently, combined administration of AZA with lenalidomide, an immunomodulatory drug with the capacity to activate CD8+ T cells which also has the capacity to salvage patients with relapsed myeloid malignancies who relapse post-transplant, would be of interest 25 .
In conclusion, our data demonstrate a potentially important role for AZA in the management of selected patients with relapsed AML or MDS after an allograft. Given its acceptable toxicity and ease of administration these results highlight a role for AZA as a novel treatment strategy in patients with recurrent disease. The development of cellular or pharmacological strategies with the capacity to increase response rates is a priority.
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